Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Abvc Biopharma (ABVC) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Abvc Biopharma (ABVC) over the last 14 years, with Q3 2025 value amounting to -$1.3 million.

  • Abvc Biopharma's Income from Continuing Operations fell 16414.47% to -$1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.4 million, marking a year-over-year decrease of 384.0%. This contributed to the annual value of -$5.3 million for FY2024, which is 3649.15% up from last year.
  • According to the latest figures from Q3 2025, Abvc Biopharma's Income from Continuing Operations is -$1.3 million, which was down 16414.47% from -$2.3 million recorded in Q2 2025.
  • Over the past 5 years, Abvc Biopharma's Income from Continuing Operations peaked at -$487431.0 during Q3 2024, and registered a low of -$6.9 million during Q4 2021.
  • Over the past 5 years, Abvc Biopharma's median Income from Continuing Operations value was -$1.9 million (recorded in 2022), while the average stood at -$2.4 million.
  • As far as peak fluctuations go, Abvc Biopharma's Income from Continuing Operations plummeted by 40928.62% in 2022, and later soared by 8552.79% in 2024.
  • Abvc Biopharma's Income from Continuing Operations (Quarter) stood at -$6.9 million in 2021, then soared by 34.78% to -$4.5 million in 2022, then surged by 84.44% to -$700309.0 in 2023, then decreased by 13.74% to -$796527.0 in 2024, then crashed by 61.64% to -$1.3 million in 2025.
  • Its Income from Continuing Operations stands at -$1.3 million for Q3 2025, versus -$2.3 million for Q2 2025 and -$944190.0 for Q1 2025.